Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Virios Therapeutics, Inc. (VIRI)

0.98   0.04 (4.26%) 09-27 11:31
Open: 0.95 Pre. Close: 0.94
High: 0.99 Low: 0.95
Volume: 31,297 Market Cap: 19(M)

Technical analysis

as of: 2023-09-27 11:20:37 AM
Short-term rate:       
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Mid-term rate:       
Target: Six months: 1.32     One year: 1.54
Support: Support1: 0.82    Support2: 0.69
Resistance: Resistance1: 1.13    Resistance2: 1.32
Pivot: 0.97
Moving Average: MA(5): 0.94     MA(20): 1
MA(100): 1.41     MA(250): 0.78
MACD: MACD(12,26): -0.1     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 43.7     %D(3): 37.3
RSI: RSI(14): 42.4
52-week: High: 2.42  Low: 0.21
Average Vol(K): 3-Month: 582 (K)  10-Days: 168 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ VIRI ] has closed below upper band by 48.8%. Bollinger Bands are 75% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.95 - 0.96 0.96 - 0.96
Low: 0.9 - 0.91 0.91 - 0.91
Close: 0.93 - 0.94 0.94 - 0.95

Company Description

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.

Headline News

Mon, 18 Sep 2023
Virios Therapeutics Announces Termination of At-The-Market Sales Agreement - Yahoo Finance

Tue, 12 Sep 2023
Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023 - Yahoo Finance

Mon, 21 Aug 2023
Is Virios Therapeutics Inc (VIRI) a Leader in the Biotechnology Industry? - InvestorsObserver

Mon, 14 Aug 2023
Virios Therapeutics Announces Halt to At-The-Market Offering Sales - Yahoo Finance

Sat, 12 Aug 2023
Virios Therapeutics, Inc. (NASDAQ:VIRI) Q2 2023 Earnings Call Transcript - Yahoo Finance

Tue, 25 Jul 2023
Virios Therapeutics Inc (VIRI) Up 1.86% in Premarket Trading - InvestorsObserver

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 19 (M)
Shares Float 16 (M)
% Held by Insiders 12.4 (%)
% Held by Institutions 8.3 (%)
Shares Short 465 (K)
Shares Short P.Month 590 (K)

Stock Financials

EPS -0.32
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.25
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -67.7
Return on Equity (ttm) -128.1
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow -8 (M)
Levered Free Cash Flow -5 (M)

Stock Valuations

PE Ratio -3.17
PEG Ratio 0
Price to Book value 3.92
Price to Sales 0
Price to Cash Flow -2.49

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.